PolyPid Ltd. (NASDAQ:PYPD) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of PolyPid Ltd. (NASDAQ:PYPD) have received an average recommendation of “Moderate Buy” from the six analysts that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $12.25.

PYPD has been the subject of a number of analyst reports. HC Wainwright reissued a “buy” rating and issued a $13.00 price objective on shares of PolyPid in a research report on Wednesday, February 11th. Wall Street Zen raised shares of PolyPid from a “sell” rating to a “hold” rating in a research report on Saturday, March 14th. Finally, Weiss Ratings downgraded shares of PolyPid from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, May 1st.

PolyPid Price Performance

Shares of PYPD opened at $5.07 on Tuesday. The firm has a 50-day moving average of $4.51 and a 200-day moving average of $4.33. PolyPid has a one year low of $2.77 and a one year high of $5.20. The company has a market cap of $96.74 million, a PE ratio of -2.65 and a beta of 1.42.

PolyPid (NASDAQ:PYPD) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.35) EPS for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.12. Analysts expect that PolyPid will post -1.34 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. AIGH Capital Management LLC lifted its stake in shares of PolyPid by 18.7% during the 1st quarter. AIGH Capital Management LLC now owns 1,593,587 shares of the company’s stock worth $6,980,000 after buying an additional 250,615 shares during the last quarter. ADAR1 Capital Management LLC acquired a new stake in shares of PolyPid during the 4th quarter worth about $451,000. XTX Topco Ltd lifted its stake in shares of PolyPid by 50.0% during the 4th quarter. XTX Topco Ltd now owns 32,661 shares of the company’s stock worth $142,000 after buying an additional 10,888 shares during the last quarter. Renaissance Technologies LLC acquired a new stake in shares of PolyPid during the 1st quarter worth about $81,000. Finally, Jane Street Group LLC acquired a new stake in shares of PolyPid during the 4th quarter worth about $66,000. Institutional investors own 26.47% of the company’s stock.

PolyPid Company Profile

PolyPid Ltd is a clinical‐stage biotechnology company focused on polymer‐based drug delivery technologies designed to enhance the performance of therapeutic agents at mucosal surfaces. Leveraging its proprietary Mucoadhesive & Mucus‐Penetrating (MMP) platform, PolyPid develops long‐acting formulations for ocular, oral and pulmonary indications. Its lead candidates include OncoTears and OralTear, therapies targeting dry eye and dry mouth conditions, respectively, as well as Paclical, a polymer‐formulated paclitaxel designed to improve tolerability and antitumor activity in oncology patients.

Founded in 2003 and headquartered in Jerusalem, Israel, PolyPid has assembled an international patent portfolio covering key markets in North America, Europe and Asia.